USFDA Flags Five Observations for US Unit of Jubilant Pharmova

Jubilant Pharmova Ltd, a leading pharmaceutical company, recently addressed regulatory developments with its subsidiary Jubilant Cadista, which underwent a USFDA inspection following the closure of its Salisbury manufacturing facility.

USFDA Inspection of Jubilant Cadista Facility

Jubilant Cadista Pharmaceuticals Inc., a subsidiary of the Company, recently underwent an inspection by the United States Food and Drug Administration (USFDA) at its solid oral formulations facility in Salisbury, Maryland, USA. The inspection resulted in five observations, none of which were repeated from previous inspections. Jubilant Cadista is committed to addressing these observations and will submit a comprehensive action plan to the USFDA within the prescribed timeline.  

Closure of Manufacturing Operations

It is important to note that the Salisbury facility is no longer expected to manufacture any products, as its manufacturing operations have been closed, as previously disclosed on April 18, 2024. 

About Jubilant Pharmova 

Jubilant Pharmova Limited, headquartered in Noida, India, is a global pharmaceutical company specialising in radiopharmaceuticals, allergy immunotherapy, drug discovery and proprietary novel drugs addressing oncology and autoimmune diseases. It operates manufacturing facilities in India, the US and Canada, with a presence in markets like the US, India and China. Committed to sustainability, it has reduced energy and water consumption, cut greenhouse gas emissions and achieved a 25.2% gender diversity ratio.

Jubilant Pharmova Share Performance 

As of January 17, 2025, at 10:50 AM, the shares of Jubilant Pharmova Ltd are trading at ₹922.30 per share, reflecting a marginal decline of 0.027% from its previous day’s closing price. The stock has experienced notable fluctuations over the recent months, with a sharp decline of 15.51% in its value over the past month. When compared to its performance a year ago, the stock has registered an overall decline of 14.59%.  

Jubilant Pharmova Ltd has seen a wide range in its stock price over the last 52 weeks, with a high of ₹1,309 per share and a low of ₹532 per share. These figures highlight the significant volatility in the stock’s performance during this period.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.